Gregory M. Bokar

Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada.

Sunovion Pharmaceuticals Europe Ltd. is a British European pharmaceutical company founded in 2013 that is dedicated to improving the lives of patients through the supply of essential medicines. The company is based in London, UK. The company commercializes and distributes a portfolio of specialty brands and hospital products in 40 countries worldwide, both directly and through strategic partnerships. The company's vision is to become a recognized partner of choice through their commercial excellence, patient focus, and presence across the globe. Sunovion Pharmaceuticals Europe aims to have a positive impact on society through their pioneering focus on their environment, social, and governance (ESG) goals.

Sunovion CNS Development Canada Ulc develops pharmaceuticals products. The company is headquartered in Vancouver, Canada.